Enabling flexible and cost-saving manufacturing for life-saving biologic therapies.
Chromatan is commercializing a new purification platform to de-bottleneck large-scale manufacturing of life-saving biologics . We have shown up to 15-fold improvements and 65% cost reduction in multiple pilot studies with large biotechs like Merck and Takeda.
In 2022, ChromaTan was awarded a $2 M Phase IIB SBIR grant from the NIH. We are raising a bridge round of $1 Million for market launch of our process development system in Q4 2022